• METTL16–SENP3–LTF Axis in HCC Ferroptosis

  2026-08-24

  Wang et al. identify a METTL16–IGF2BP2–SENP3–LTF regulatory axis that links m6A-dependent RNA control, SUMO-related protein stability, and iron handling in hepatocellular carcinoma. The findings establish a mechanistic framework for understanding ferroptosis resistance and suggest that this axis may be therapeutically relevant, while remaining distinct from direct evidence for NF-κB pathway modulation.

• Triterpene Prodrug for Targeted OSCC Therapy

  2026-08-23

  This 2024 ACS Applied Materials & Interfaces study reports a carrier-free, self-assembled triterpene prodrug designed to improve oral squamous cell carcinoma chemotherapy through glucose-associated uptake, ROS-responsive release, and dual triterpene activity. Its central innovation is a thioketal-linked glycyrrhetinic acid construct that helps generate the oxidative stimulus needed to accelerate its own drug release alongside ginsenoside Rh2.

• 5-Azacytidine Triggers DNA Damage in Myeloma Cells

  2026-08-22

  The reference study shows that 5-azacytidine kills therapy-sensitive, therapy-resistant, and multidrug-resistant multiple myeloma cells through ATR-associated DNA double-strand break responses and both caspase-dependent and caspase-independent apoptosis. Its synergistic activity with doxorubicin and bortezomib provides a mechanistic preclinical rationale for combination treatment, while the selective effects observed in nonmalignant cells support further investigation.

• Temafloxacin Pharmacokinetics: Evidence and Limits

  2026-08-21

  This 1991 review integrates temafloxacin serum kinetics, tissue distribution, renal elimination, and pharmacodynamic considerations into a practical dosing framework. Its value today is methodological: it shows how bioavailability, half-life, clearance, and exposure–response reasoning can guide regimen design, while also defining the limits of transferring fluoroquinolone data to other antimicrobials.

• NEP S-S-S Phosphorylation Controls Influenza vRNP Export

  2026-08-21

  The reference study identifies phosphorylation of the conserved NEP S23–S25 serine motif as a functional checkpoint for influenza vRNP nuclear export. Through viral genetics, kinase perturbation, peptide competition, and mouse experiments, it connects this modification to viral replication, infectivity, and virulence while highlighting a potential antiviral vulnerability.

• Epigenetic MCL-1 Targeting in Glioblastoma

  2026-08-20

  The reference study identifies a super-enhancer near Mcl-1 in glioblastoma and shows that disrupting this regulatory element can sensitize tumor models to BCL-2/BCL-XL inhibition. Its combination of chromatin profiling, pharmacological perturbation, apoptosis assays, and patient-derived xenografts provides a mechanistic framework for overcoming MCL-1-associated treatment resistance.

• Torin2: Selective mTOR Inhibition in Cancer Research

  2026-08-20

  Torin2 is a potent mTOR inhibitor for mechanistic cancer research, pathway studies, and cellular response assays. Its product dossier reports nanomolar potency, cellular kinase selectivity, oral availability, and activity in medullary thyroid carcinoma models, while current RNA polymerase II research defines an apoptosis mechanism that should not be automatically attributed to Torin2.

• Meropenem Workflows for Resistance Research

  2026-08-19

  Build reproducible Meropenem assays for susceptibility testing, resistance dynamics, and Gram-negative infection models. This practical workflow connects PBP biology and exposure control with nanoparticle-enabled septicemia treatment research while separating exploratory assay conditions from clinical interpretation.

• GST-Driven Lambda-Cyhalothrin Resistance in M. usitatus

  2026-08-18

  The reference study combines GST expression analysis, antioxidant measurements, apoptosis markers, and chemical inhibition to show that GST-mediated antioxidant defense contributes directly to lambda-cyhalothrin resistance in Megalurothrips usitatus. Inhibiting GST with diethyl maleate reduced antioxidant capacity and markedly increased insecticide sensitivity, providing a mechanistic framework for resistance monitoring and intervention.

• Measuring Drug Responses Beyond Cell Viability

  2026-08-18

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central contribution is a clearer framework for separating proliferative inhibition from cell killing and for interpreting how their proportions and timing vary across drug treatments.

• Annular Sector Microneedles for Glaucoma Gene Therapy

  2026-08-17

  The reference study introduces an annular sector-shaped microneedle patch for localized co-delivery of nicotinamide and Nmnat1 gene-loaded lipid nanoparticles to the trabecular meshwork. In cellular and dexamethasone-induced mouse models, this strategy improved mitochondrial-related pathology, lowered intraocular pressure, and reduced trabecular meshwork fibrosis, providing a targeted alternative to therapies that only modify aqueous humor turnover.

• Dicloxacillin: Intra- and Extracellular PK/PD

  2026-08-17

  The reference study examined dicloxacillin activity against Staphylococcus aureus in both THP-1 cellular models and a murine peritonitis model, directly addressing the often-overlooked intracellular compartment. Its central finding was that free-drug time above the MIC best predicted efficacy in both compartments, while differences between single-dose in vitro and in vivo extracellular results highlighted the importance of exposure duration and experimental timing.

• Carbapenemase Gene Dynamics in Enterobacter cloacae

  2026-08-16

  A 2025 BMC Microbiology study examined carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates collected from eight teaching hospitals in Guangdong, China. By combining gene localization, susceptibility testing, conjugation, mobile-element analysis, and ERIC-PCR typing, the study clarifies why plasmid-borne blaNDM-1 can support both multidrug resistance and interhospital dissemination.

• Aztreonam Workflows for Gram-Negative Resistance

  2026-08-15

  Build isolate-centered assays that connect Aztreonam susceptibility with carbapenemase gene location, plasmid transfer, and resistance dynamics. The same reagent can also support carefully separated bone marrow progenitor and hepatic cytochrome P450 research modules.

• L. gasseri ATCC33323 and E-Cadherin in Colitis

  2026-08-15

  A 2024 PLOS Pathogens study identifies an NR1I3–CDH1–E-cadherin pathway through which Lactobacillus gasseri ATCC33323 protects the intestinal barrier in DSS-induced colitis. Its combination of probiotic treatment, intestinal E-cadherin perturbation, transcriptional analysis, and in vitro validation provides a mechanistic framework for evaluating strain-specific microbiota interventions.

452 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page